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The efficacy of temozolomide strongly depends on O
6-alkylguanine DNA-alkyl transferase (AGAT), which repairs DNA damage
caused by the drug itself. Low-dose protracted temozolomide administration can decrease AGAT activity. The main end point of the
present study was therefore to test progression-free survival at 6 months (PFS-6) in glioblastoma patients following a prolonged
temozolomide schedule. Chemonaı ¨ve glioblastoma patients with disease recurrence or progression after surgery and standard
radiotherapy were considered eligible. Chemotherapy cycles consisted of temozolomide 75mg/m
2/daily for 21 days every 28 days
until disease progression. O
6-methyl-guanine-DNA-methyl-tranferase (MGMT) was determined in 22 patients (66.7%). A total of 33
patients (median age 57 years, range 31–71) with a median KPS of 90 (range 60–100) were accrued. The overall response rate was
9%, and PFS-6 30.3% (95% CI:18–51%). No correlation was found between the MGMT promoter methylation status of the tumours
and the overall response rate, time to progression and survival. In 153 treatment cycles delivered, the most common grade 3/4 event
was lymphopoenia. The prolonged temozolomide schedule considered in the present study is followed by a high PFS-6 rate; toxicity
is acceptable. Further randomised trials should therefore be conducted to confirm the efficacy of this regimen.
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Glioblastoma multiforme (GBM), the most aggressive brain
tumour in adults despite, advances in diagnosis and treatment
made over the past two decades, is still incurable (Brandes, 2003).
Every effort should, therefore, be made to develop new approaches
that maximise an active drug, such as temozolomide (TMZ), which
is the backbone in the treatment of brain tumours. However, the
efficacy of this therapy is limited by the presence of intrinsic or
acquired resistance mechanisms. Temozolomide exerts its activity
by means of DNA methylation at the N
7 and O
6 position of guanine
and at the O
3 position of adenine (Denny et al, 1994). Although O
6-
methylguanine accounts for few adducts formed by TMZ, it plays a
critical role in the cytotoxicity of the drug. The DNA repair
protein, O
6-alkyl-guanine-DNA-alkyltransferase (AGAT), encoded
by the MGMT gene, reverts resistance to TMZ by removing
cytotoxic methyl adducts from the O
6 position of guanine. As
AGAT removes methyl adducts from DNA via a suicide mechan-
ism, it has also been suggested that protracted exposure to an
alkylating agent may not only saturate AGAT copies available
within cancer cells, but may also inactivate the new molecules
while they are being synthesised, thus leading to AGAT ‘depletion’
and overcoming the inherent resistance of glioma cells.
Tolcher et al (2003) showed that mean AGAT activity decreased
by 63% in peripheral blood mononucleal cells (PBMC) after 14
days of protracted TMZ treatment, and by 73% after 21 days;
these low levels persisted up to day 28. In the present study, AGAT
activity in PBMC has been used as a pharmacodynamic
surrogate end point for AGAT depletion, although changes in
AGAT activity in PBMC may not reflect changes in tumour tissues.
A phase I study was performed using this TMZ schedule (3 weeks
on/1 week off) in patients with advanced-stage solid malignancies
(Denis et al, 2000). Dose-limiting toxicity was thrombocytopenia,
the maximum-tolerated dose being 100mg/m
2. However, as
toxicity was detected only after two courses of treatment, no
definitive conclusions could be drawn regarding the long-term
toxicity of the regimen at this dosage. The aim of the present
phase II study was therefore to evaluate the effect of a prolonged
TMZ schedule of 75mg/m
2/daily for 21 days every 28 days in
relation to progression-free survival at 6 months (PFS-6),
response, toxicity and any correlation with MGMT gene
promoter methylation status, in patients with recurrent or
progressive GBM.
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sMATERIALS AND METHODS
Eligibility
Criteria for eligibility were: histological diagnosis of GBM, age
X18 years, Karnofsky Performance Score (KPS) X60, normal
baseline counts for neutrophils X1500/ml and platelets X100000/
ml; transaminases and alkaline phosphatase levels p1.5 times the
upper normal limits; bilirubin and creatinine levels p1.25 times
the upper normal limits; previous surgery followed by standard
radiotherapy (60Gy/30 fractions). Unequivocal evidence of disease
recurrence or progression at gadolinium-enhanced MRI neuro-
imaging was also required. Patients accrued had at least one
enhancing measurable lesion with a diameter of X2cm, evaluated
at least 3 months after the end of radiotherapy. Brain imaging,
performed within 2 days after surgery, showing residual disease
with the above characteristics was mandatory for patients under-
going repeat surgery for recurrence. All patients accrued had been
on a stable dose of corticosteroids for at least 2 weeks before
initiation of therapy. Patients with childbearing potential were to
use effective contraception. Pregnant or breast-feeding patients
were ineligible, as were patients who had previously received
cytotoxic therapy, presented active infection or other uncontrolled
diseases, psychiatric disturbances and/or a history of cancer other
than resected nonmelanoma skin cancer or carcinoma in situ of
the uterine cervix.
Availability of tumour specimens to perform the assessment of
MGMT promoter methylation status was required for all patients. The
study, approved by the Institutional Review Boards of all participating
centres, was conducted according to the principles of the Declaration
of Helsinki and the rules of Good Clinical Practice. All patients signed
a form giving their fully informed consent to participate.
Treatment regimen
All patients were given TMZ 75mg/m
2/daily for 21 days every 28
days. No dose escalation was allowed. Patients fasted for at least 2h
before, and 2h after, TMZ administration. As continuous daily
TMZ can cause lymphopoenia, potentially increasing the risk of
opportunistic infections, patients received oral trimethoprim-
sulphamethoxazole to prevent Pneumocystis carinii pneumonia if
the lymphocyte count fell to o500/ml (Kovacs and Masur, 2000).
Antiemetic prophylaxis with metoclopramide or a 5-hydroxytrip-
tamine3 antagonist was also given.
Dose modifications
Patients were closely monitored for toxicity throughout cycles, all
adverse events being recorded and graded according to the
common toxicity criteria of the National Cancer Institute, version
3.0. (http://ctep.cancer.gov/forms/CTCAEv3.pdf).
Haematology was performed weekly, while complete bio-
chemistry was assessed once per cycle, preferably on day 28.
Chemotherapy was given if neutrophils were X1500/ml, lympho-
cytes X500/ml and platelets X100000/ml; otherwise treatment was
delayed for a maximum of 3 weeks until adequate recovery. If
blood counts analysed throughout 3 weeks were still unsatisfac-
tory, treatment was stopped. In cases of XG3 haematological
toxicity at nadir or reversible G3 nonhaematological toxicity
(except for nausea/vomiting), TMZ was reduced by 25%. If G4
haematological or G3 nonhaematological toxicity reappeared
notwithstanding dose reductions, or if any type of nonhaemato-
logical G4 toxicity was observed, chemotherapy was interrupted.
The use of growth factors in order to maintain high blood
counts and to administer chemotherapy at fixed intervals was
proscribed. Patients were kept at the lowest corticosteroid dosage
allowed in relation to their neurological status.
Efficacy measures
Progression-free survival was evaluated from the start of
chemotherapy to progression; median survival (MST) was
calculated from the start of chemotherapy to death for any reason.
In this intent-to-treat study, data on all registered patients were
included in the statistical analysis.
PFS, PFS-6 and MST were calculated using the Kaplan–Meier
method (Kaplan & Meier, 1958); differences in progression and
overall survival (OS) were evaluated by the log-rank test for
statistical significance.
Patients were evaluated for response using clinical and
neurological examinations (performed monthly before each cycle)
and MRI or CT neuroimaging performed every two cycles, or
earlier if indicated, according to Macdonald’s criteria (Macdonald
et al, 1990). Neurological status was assessed by considering signs
and symptoms possibly correlated with progression, as compared
to the previous examination; each variation in daily corticosteroids
dosage was recorded.
Responses were confirmed as complete or partial if they were
constant at subsequent scans obtained at least 4 weeks apart from
each other. An independent central review of CT and MRI scans
was made for patients achieving complete (CR) or partial (PR)
response or stable disease (SD), evaluated by local investigators.
Patients were withdrawn if they had progressive disease, unac-
ceptable toxicity, or retracted their consent.
DNA extraction and methylation-specific polymerase chain
reaction
DNA from 10mm paraffin sections of cerebral lesion was modified
by sodium bisulphite, which converts unmethylated cytosine to
uracil, according to the procedure of Herman et al (1996).
Modified DNA was submitted for methylation specific PCR (MSP)
by a nested-PCR protocol (Palmisano et al, 2000). As the quality of
DNA obtained from formalin-fixed paraffin-embedded tumour
tissue affects the success rate of MSP, in some cases MGMT
methylation status was determined by a different nested-MSP
approach, with a first pair of primers to obtain smaller amplicons
(129bp), for which forward and reverse primers have been
described (Palmisano et al, 2000; van Engeland et al, 2003).
Statistical analysis
The trial was a phase II study, with PFS-6 percentage as the main
end point. According to the Minimax design (Simon, 1989), our
study, with its sample size of n¼33, had a 5% probability of
rejecting (a) the hypothesis of a PFS-6 10% (P0) and a 90%
probability of accepting (1-b) the hypothesis of a PFS-6 of 30%
(P1). If two, or fewer of the first 22 patients were progression free
at 6 months, PFS-6 would be considered o10% and the study
terminated. Otherwise, the study would be completed, the accrual
target being 33 patients. If six or fewer of the 33 patients were
progression-free at 6 months, then no further investigation of the
treatment regimen was considered warranted. PFS, PFS-6 and OS
were calculated using the Kaplan–Meier method (Kaplan and
Meier, 1958), and differences in progression and survival in
relation to prognostic factors were evaluated with the log-rank test.
Student’s T and the Mann–Whitney U-tests were used to analyse
normally and non-normally distributed variables between groups.
All calculations were performed using S-PLUS software (MathSoft
Inc., Seattle, WA, USA).
RESULTS
Patient characteristics
From November 2003 to September 2005, 33 patients (13 females;
median age 57, range 31–71 years; median KPS 90, range 60–100)
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patients were evaluated for drug activity and toxicity.
Methylation specific PCR analysis
Methylation specific PCR (MSP) analysis was performed in all 33
patients enrolled in the trial. However, results were evaluable only
in 22 patients, with an MSP success rate of 66%; this finding is
comparable to those reported by other authors (Hegi et al, 2005).
Among 22 patients for whom MSP was evaluable, 10 (45.5%)
presented MGMT promoter methylated and 12 unmethylated
(54.5%) status. No differences were found between patients with
MGMT promoter methylated and those with unmethylated status
for age (P¼0.16), gender (P¼0.39), performance status (PS)
(P¼0.72), time-intervals between surgery and start of chemother-
apy (P¼0.21), or between the end of radiotherapy and start of
chemotherapy (P¼0.15). All patients had undergone one surgical
procedure and full-dose radiotherapy, completed at least 3 months
previously, but none had been given cytotoxic or cytostatic drugs.
Progression-free survival
All patients were followed-up to disease progression. The
percentage of patients without progression at 6 months (PFS-6)
was 30.3% (95%CI: 18–51%). Overall, the median PFS was 16.1
weeks (95%CI: 12.4–27.3), 15.6 weeks (CI: 11–NA) and 11.9 weeks
(CI: 10.3–31.6) in patients with MGMT promoter methylated
status and in patients with unmethylated MGMT promoter status,
respectively. No significant differences were found between PFS,
evaluated using the log-rank test, in relation to age (P¼0.42), KPS
(P¼0.77), type of surgery (P¼0.58) and MGMT promoter
methylated or unmethylated status (P¼0.86).
Response
Among the 33 evaluable patients, one CR (3%) and two PR (6%)
were obtained, with an overall response rate of 9% (CI: 0–18.8%).
Seventeen patients had SD (51%; CI: 34.4–68.6%). All radiological
responses were confirmed by an independent centralised review,
and stable or decreased steroid dosage was confirmed in all
patients on recording responses, which had a median duration of
30.4 weeks, the median duration of disease stabilisation being 25.6
weeks. No correlations were found between response to therapy
and age (P¼0.32), KPS (P¼0.96), time-interval between surgery
(P¼0.19) or end of radiotherapy (P¼0.38), MGMT promoter
methylated or unmethylated status (P¼0.63) in responders
(CRþPR) and SD patients vs PD patients.
Overall survival
Median survival as from the start of chemotherapy was 40 weeks
(CI: 31–63), although this outcome may have been influenced by
second-line treatments, 12 patients being treated with nitrosourea-
based regimens, 3 with carboplatin and etoposide, 3 with new
experimental drugs, and 15 with no other treatments. In all, 73%
(CI: 59–90%) and 38% (CI: 24–59%) of the patients were alive at 6
and 12 months, respectively. Median survival and percentage of
patients alive at 1 year in cases with methylated MGMT promoter
status were 48.2 weeks (CI: 29–NA) and 50% (95% CI: 27–93%),
respectively; in patients with unmethylated MGMT promoter
status, these figures were 34.7 weeks (95% CI: 30–64.1) and
21.4% (CI: 8–58%), respectively. Only KPS (o90 vs X90) was
related to survival (P¼0.05) (Figure 1).
Toxicity
A total of 153 treatment cycles were given to 33 patients, the
median number of cycles per patient was three (range 1–15). The
most common adverse event was lymphopoenia (Table 2). As the
cycles were delivered, a clear trend toward an increase in
lymphopoenia was observed, being present in 30% of patients
during the first three cycles, and in 55% of the patients in the
subsequent cycles.
Although none of the patients had pneumocistis carinii
pneumonia, five (13.6%) had grade 1–3 infections (one herpes
zoster, one urinary infection and three upper respiratory tract
infection) associated with lymphopoenia grade 1 (one patient),
grade 2 (two patients) and grade 3 (two patients). The most
commonly found nonhaematological symptoms and signs of
toxicity were constipation and grade 1–3 asymptomatic
transaminase increase, observed in seven patients (21.2%). Eight
cycles (5.2%) were delayed for a median time of 1 week (recovery
Table 1 Characteristics of patients
No. of patients (%)
Gender
Female 13 (39)
Male 20 (61)
Age (years)
Median 57
Range 31–71
KPS
Median 90
Range 60–100
Extent of resection
Gross total resection 13 (39)
Partial resection or biopsy 20 (61)
Previous treatment
Primary resection 33 (100)
Radiotherapy 33 (100)
Chemotherapy 0
Repeat surgery for recurrence 1
Cycles of temozolomide
p31 8
4–6 7
7–9 6
410 2
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Figure 1 Thin line PFS. Thick line: OS.
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infections (25%) and grade 4 neutropenia (25%).
The most common reason for drug discontinuation was disease
progression, which occurred in 93.9% of patients. One patient died
of pulmonary embolism, probably unrelated to TMZ administra-
tion; one discontinued treatment due to prolonged (7 weeks) grade
4 pancytopenia.
Based on the supposition that MGMT, a potent drug resistance
gene, might be implicated in the protection of haematopoietic stem
cells during chemotherapy (Gerson, 2004) a search was made for a
correlation between MGMT promoter status and toxicity. How-
ever, MGMT promoter methylation status was determined on
tumour samples, and not in blood, thus indicating only an indirect
correlation between MGMT and toxicity. Grade 3–4 leukopenia
was observed in three patients with methylated MGMT promoter
and in one patient with unmethylated MGMT promoter, lympho-
poenia grade 3 was observed in four patients with methylated
MGMT promoter, and in one with unmethylated MGMT promoter.
DISCUSSION
In GBM patients with first recurrence, TMZ is active at a standard
single daily dose of 150–200mg/m
2, administered for five days
every 4 weeks. In the three available studies investigating this
regimen in this setting, PFS-6 was 21% (Yung et al, 2000) (CI:13–
29%), 18% (Brada et al, 2001) (CI:11–24%), and 24% (Brandes
et al, 2002) (CI:14–42%). As the antitumour activity of TMZ
depends on the level of AGAT within tumour cells, several trials
have aimed to deplete AGAT via a continuous dosing schedule
(Tolcher et al, 2003). In their phase II study with continuous TMZ
administration at a dosage of 75mg/m
2/day over a 6-week period
with 4 weeks’ rest, in 28 pretreated GBM patients, Khan et al
achieved a PFS-6 of 19%, a median PFS 2.3 months and zero
responses. This schedule thus allowed a higher dose intensity
(1260mg/m
2) over 4 weeks than the standard schedule (1000mg/m
2)
with good tolerability, although the results did not support its use
in patients with recurrent GBM. Wick et al (2004) treated 21 GBM
patients with a different 28-day period continuous schedule (TMZ
at 150mg/m
2 delivered for 1-week on/1-week off) with a drug
intensity of 2100mg/m
2 and AGAT (Tolcher et al, 2003) was
depleted: a PFS-6 of 48% was obtained (43% patients were
pretreated with 1–2 chemotherapy regimens) with modest toxicity.
However, on using the same regimen, Chinot et al (2005) obtained
a PFS-6 of only 21% in 29 inoperable previously untreated GBM
patients.
We treated recurrent chemonaı ¨ve GBM patients with a
continuous TMZ schedule for 21 days every 28 days, and a PFS-
6 of 30.3% was obtained. Our findings may have been influenced
by several factors: chemotherapy administered at relatively low
doses while following a frequent metronomic schedule may have
optimised the antiangiogenic effect of cytotoxic agents, providing
better results than an intensified weekly schedule (Kurzen et al,
2003). Moreover, a high-dose intensity (1575mg/m
2) was achieved
and AGAT depletion was more prolonged than in a weekly
schedule, in which recovery of AGAT activity begins immediately
after 7 days (Tolcher et al, 2003).
The results reported in studies on MGMT gene promoter status
are controversial. It has been maintained that MGMT promoter
methylation assessed by MSP is associated with a longer survival in
GBM patients treated with radiotherapy and TMZ (18.2 vs 12.2
months, Po0.001) (Hegi et al, 2005). However, Paz et al (2004)
reported that MGMT promoter methylation was correlated with
response to standard TMZ, but not with OS. Findings made using
alternative methods (immunohistochemistry or activity tests) are
contradictory, some confirming (Friedman et al, 1998) and others
denying (Middleton et al, 1998) a relationship with time to
progression or response to TMZ.
To our knowledge, ours is the first trial to study correlations
between MGMT promoter methylation status, assessed by MSP,
and treatment outcome with a continuous TMZ schedule. Findings
for/MSP were available in 22 (66.7%) of the 33 patients enrolled in
the study; this percentage is similar to those reported (59–67%) in
MSP studies made by other authors (Hegi et al, 2004; Hegi et al,
2005). In our study, an overall median PFS of about 4 months and
a PFS-6 of 30.3% were obtained: these results appear superior to
those obtained with the standard TMZ schedule. In 22 patients for
whom MGMT promoter status was available, no significant
difference was found between MGMT promoter methylated or
unmethylated patients for median PFS and PFS-6 (15.6 weeks and
20% vs 11.9 weeks and 21.4%). This suggests that AGAT depletion
achieved with protracted TMZ increases the sensitivity of
unmethylated tumours to TMZ, leading to an increase in PFS
and OS which would have been less than that obtained by us if
these patients had been treated with the traditional TMZ schedule.
However, this observation, based on a small number of patients,
should be demonstrated by findings from prospective studies with
patients stratified according to methylation status, as in the
ongoing phase III RTOG/EORTC study.
The standard TMZ schedule (Brada et al, 2001; Yung et al, 2000)
incurs higher grade 3/4 thrombocytopenia (7–10% vs 3) and lower
grade 3/4 neutropenia (4–4.5% vs 12) rates than our 3-week on/1-
week off schedule. Cumulative lymphopoenia was observed in
45.4% of our patients, this outcome being comparable to those
reported by other authors following other protracted schedules
(Brock et al, 1998; Khan et al, 2002; Su et al, 2004; Wick and
Weller, 2005). This high incidence of lymphopoenia may have been
due in part to the concomitant administration of steroids: 75% of
patients received both steroids and continuous TMZ. The standard
TMZ schedule rarely leads to lymphopoenia, no such cases being
reported in 250 GBM patients treated in phase II–III trials (Yung
et al, 2000; Brada et al, 2001).
Although the number of severe haematologic events observed by
us may be of limited statistical power, we observed an association
Table 2 Toxicity per patient
Grade 1 no. of
patients (%)
Grade 2 no. of
patients (%)
Grade 3 no. of
patients (%)
Grade 4 no. of
patients (%)
Neutropenia 1 (3) 2 (6) 2 (6) 2 (6)
Lymphopoenia 1 (3) 6 (18.2) 8 (24.2) 0
Thrombocytopenia 1 (3) 0 0 1 (3)
Anemia 5 (15.2) 1 (3) 1 (3) 0
Nausea 0 2 (6) 1 (3) 0
Constipation 4 (12.1) 4 (12.1) 1 (3) 0
Increased transaminase 5 (15.2) 1 (3) 1 (3) 0
Infection with lymphopoenia 1 (3) 3 (9.1) 1 (3) 0
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and MGMT status. Based on experimental evidence indicating low
AGAT activity in bone marrow CD34 cells (Gerson et al, 1996), it
may be suggested that haematological progenitors are especially
sensitive to strategies that inactive AGAT: when O
6 benzylguanine,
an AGAT specific inhibitor, is added to BCNU, haematological
toxicity increases (Friedman et al, 2000). A correlation between
AGAT activity in PBMC and haematological toxicity has been
demonstrated by Tolcher et al (2003) in patients treated with a
prolonged schedule. However, in our study MGMT promoter
methylation status was assessed only on tumour samples, and
MGMT promoter methylation may vary among different tissues.
Based on these considerations it would be interesting to conduct a
prospective trial studying MGMT expression in blood and tumour
samples in order to understand the activity of temozolomide and
its toxicity profile as this would be conducive to personalising drug
delivery.
In June 2005, TMZ concomitant with radiotherapy followed by
six cycles of maintenance chemotherapy became standard therapy
worldwide (Stupp et al, 2005). The present study will therefore
probably be the last classic phase II trial to be performed using an
alternative TMZ schedule as first-line chemotherapy in chemo-
naı ¨ve and recurrent patients after standard radiotherapy. The
findings made indicate that a phase III trial on a larger series
should be launched in order to evaluate whether new chemo-
therapy regimens combining dose-intensity concepts with the
manipulation of chemoresistance may yield a good risk/benefit/
cost ratio in glioblastoma patients.
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